Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Public ClinicalTrials.gov record NCT01032070. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma.
Study identification
- NCT ID
- NCT01032070
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Year to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 27, 2010 (Actual)
- Primary completion
- Nov 26, 2012 (Actual)
- Completion
- Nov 26, 2012 (Actual)
- Last update posted
- Dec 12, 2024
2010 – 2012
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Dept. of Pediatric-Hematology/Oncology | Birmingham | Alabama | 35233 | — |
| Center for Cancer and Blood Disorders-Phoenix Children's Hospital | Phoenix | Arizona | 85016 | — |
| Children's Hospital of Orange County (CHOC) | Orange | California | 92868 | — |
| Stanford University and Lucile Packard Children's Hospital | Palo Alto | California | 94304 | — |
| Children's Hospital Center for Cancer and Blood Disorders | Aurora | Colorado | 80045 | — |
| Children's National Medical Center - D.C. Center for Cancer and Blood Disorders | Washington D.C. | District of Columbia | 20010 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Emory University Children's Healthcare of Atlanta Aflac Cancer Center & Blood Disorders | Atlanta | Georgia | 30322 | — |
| Johns Hopkins University School of Medicine | Baltimore | Maryland | 21287 | — |
| Dana-Farber Cancer Institute Department of Pediatric Neuro-oncology | Boston | Massachusetts | 02115 | — |
| Amplatz Children's Hospital University of Minnesota Medical Center- Pediatric Hematology Oncology | Minneapolis | Minnesota | 55455 | — |
| Steven D Hassenfeld Children's Center - New York University | New York | New York | 10016 | — |
| Columbia University Children's Hospital of New York Presbyterian Child & Adolescent Oncology Center | New York | New York | 10032 | — |
| Oregon Health & Sciences University Doembecher Children's Hospital | Portland | Oregon | 97124 | — |
| Penn State Hershey Children's Hospital | Hershey | Pennsylvania | 17110 | — |
| Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania | 15224 | — |
| Children's Medical Center, Dallas Center for Cancer and Blood Disorders | Dallas | Texas | 75235 | — |
| University of Wisconsin Pediatric Hematology/Oncology Department | Madison | Wisconsin | 53705-2275 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01032070, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2024 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01032070 live on ClinicalTrials.gov.